The complement system is an ancient and critical effector mechanism of the innate immune system as it senses, kills, and clears infectious and/or dangerous particles and alerts the immune system to the presence of the infection and/or danger. Interestingly, an increasing number of reports have demonstrated a clear role for complement in the adaptive immune system as well. Of note, a number of recent studies have identified previously unknown roles for complement proteins, receptors, and regulators in T cell function. Here, we will review recent data demonstrating the influence of complement proteins C1q, C3b/iC3b, C3a (and C3aR), and C5a (and C5aR) and complement regulators DAF (CD55) and CD46 (MCP) on T cell function during homeostasis and disease. Although new concepts are beginning to emerge in the field of complement regulation of T cell function, future experiments should focus on whether complement is interacting directly with the T cell or is having an indirect effect on T cell function via APCs, the cytokine milieu, or downstream complement activation products. Importantly, the identification of the pivotal molecular pathways in the human systems will be beneficial in the translation of concepts derived from model systems to therapeutic targeting for treatment of human disorders.
Introduction
The complement system is a powerful effector mechanism of the innate immune system composed of Ͼ30 proteins found in the circulation and tissue. Upon activation, a series of proteolytic and protein-protein interactions occurs, resulting in the opsonization of invading pathogens or dangerous particles, recruitment of leukocytes to the site of infection or injury, and/or lysis of the pathogen. In the past, complement was thought to function largely as part of the innate immune system or as an effector mechanism recruited by antibodies bound to their antigens. However, a rapidly growing body of literature has reported novel functions for complement proteins in modulating adaptive immunity, including direct and indirect effects on T cell activation. In particular, reports from several groups have highlighted roles for complement protein C1q, complement component fragments C3b, iC3b, C3a, and C5a, and complement regulators CD46 (MCP) and DAF (CD55) as modulators of T cell activation. This brief review will focus on the influence of these complement proteins on T cell function during homeostasis and disease and will highlight some differences in complement-mediated T cell responses between murine models and human physiology.
COMPLEMENT COMPONENT C1q
In addition to initiating the classical complement cascade (i.e., when C1r and C1s are present to initiate the formation of C3 convertase), the C1q protein binds apoptotic cells to enhance ingestion by phagocytes before membrane integrity of the dying cell is lost. Additionally, it has been known for some time that C1q
Ϫ/Ϫ individuals present with SLE with extremely high (93%) penetrance [1] and that C1q mice can develop autoantibodies and a SLE-like disease [2] . Furthermore, C1q
Ϫ/Ϫ mice exhibit accelerated rejection of minor histocompatibility disparate skin grafts and resistance to induction of tolerance [3] .
The mechanism for how C1q may prevent SLE in normal individuals is only beginning to be elucidated. Korb and Ahearn [4] demonstrated that C1q binds apoptotic cells through its globular head domain, which leaves the collagenlike domain available for interactions with phagocytic cells [5] . Our group and several others [6] have studied how the C1q interaction with APCs affects the phenotypic and functional state of the APC. In an entirely human autologous system, C1q bound to ingested apoptotic cells increases the production of macrophage anti-inflammatory cytokines, such as IL-27 and IL-10, while decreasing inflammatory cytokines, such as TNF-␣, and diminishing inflammasome activity [7] . Based on these data, our group recently evaluated whether macrophages interacting with C1q-bound apoptotic cells modulate T cell activation. We discovered that primary human macrophages ingesting C1q-bound late apoptotic cells decrease allogeneic and autologous Th17 and Th1 proliferation. In addition, there is a trend for increased allogeneic T reg proliferation, suggesting that C1q interaction with macrophages can skew T cell polarization, reducing T eff activity and/or suppressing the induction of autoimmunity in the tissue (Fig. 1B and [8] ). These results complement and extend those published by Lu and colleagues [9] , in which primary human DCs interacting with immobilized C1q were found to suppress allogeneic CD4 Th1 and Th17 lineages (Fig. 1A) .
The capacity of C1q to modulate T cell function has also been studied in murine models, although there appears to be some differences from the primary human systems described above. For example, Cutler et al. [10] demonstrated that in C1q Ϫ/Ϫ mice, antigen-specific T cells exhibited a significant reduction in IFN-␥ production compared with control mice. Similarly, a more recent study from the same group [11] used DCs from C1q Ϫ/Ϫ mice and found that in this context, exogenously added C1q augments the production of IL-12 by DCs and increases the number of CD4 ϩ IFN-␥ ϩ (Th1) and CD8
ϩ IFN-␥ ϩ T cells in response to DC CD40 ligation. Whereas these experiments suggest differences between mouse and human systems, they may also or alternatively reflect a difference between C1q modulation of T cell function in mice with lifetime genetic C1q Ϫ/Ϫ and thus, all of the other consequences of a lack of that molecule. Furthermore, the results in the C1q Ϫ/Ϫ model alone cannot distinguish between the function of the C1 complex (C1qϩC1rϩC1s) and thus, a defi- [9] . Primary human monocytes were cultured on immobilized C1q (C1q-DCs) or control protein BSA in the presence of GM-CSF and IL-4, and resulting DCs were stimulated with LPS and IFN-␥. C1q-DCs up-regulated IL-10 and reduced IL-6, IL-23, and IL-12 production relative to control DCs as well as the percent of allogeneic Th1, Th17, and CD4 ϩ IL-17 ϩ IFN-␥ ϩ T cells in an allogeneic MLR. (B) Based on unpublished results. Human M-CSF monocyte-derived macrophages ingested C1q-bound apoptotic lymphocytes (C1q-LAL) apoptotic cells without C1q (LAL), after which they were stimulated with low levels of LPS. The resulting "C1q-polarized macrophage" exhibited elevated PD-L1, PD-L2, and CD39; reduced CD40 surface expression; and produced greater IL-27 and IL-10 and less IL-1␤ than macrophages that had ingested LAL alone. Furthermore, the proliferation of allogeneic and autologous Th17, Th1, and CD8
ϩ IFN-␥ ϩ T cell subsets was diminished in the presence of C1q, whereas proliferation of allogeneic CD4
ϩ Foxp3 ϩ and CD8 ϩ Foxp3 ϩ T cell subsets trended toward an enhancement with C1q under these MLR conditions. ciency of the complement fragments, resulting from the activation of the classical complement cascade versus C1q Ϫ/Ϫ alone. Whereas one may expect that a lack of C1 would lead to less C3 fragment deposition and thus, less effective antigen presentation, resulting in a diminished immune response (see below and ref. [12] ), the fact that the lack of C1q inevitably leads to SLE, rather than suppressing autoimmunity, supports a direct role for C1q in APC polarization seen in the human studies [7, 13] . C1q is known to be expressed in the absence of C1r and C1s in tissue [14, 15] , is synthesized by macrophages, and is induced in response to local injury [16, 17] , as reviewed in ref. [18] . As a result, C1q predominance in perturbed tissue may serve to accelerate the ingestion of dying cells and the resolution of inflammation (as reviewed in ref. [6] ), and therefore, in this context, C1q may be considered an immunological "rheostat" or homeostatic regulator. Thus, the use of primary human cells and the evaluation of C1q specifically (in a serum-free system) represent an important approach for evaluating the effects of C1q interaction with macrophages in the tissue during low levels of inflammation, such as would occur during mild sterile injury or with decreasing danger signals to promote contraction of immune cell populations.
The presence of C1qRs on T cells themselves and the potential for specific consequences of an interaction of C1q with T cells have not been fully defined. One study from two decades ago provided evidence that human T cells express a C1qR (cC1qR), which interacts with the collagen-like domain of the molecule [19] . The expression of this C1qR is up-regulated by mitogens that induce T cell proliferation, although the addition of C1q before the addition of mitogen induced an antiproliferative signal [20] . Whereas this report presents an intriguing possibility for a direct effect of C1q on T cell function, in this study, C1q was added to T cells directly in the media, so it was not necessarily interacting with the T cells in a multivalent fashion, as is usually seen to be critical for stable C1q interactions. In addition, the assays were all conducted in cultures containing 10% FCS, so the interaction of exogenously added C1q with other serum proteins present cannot be ruled out as playing a contributing role in the C1q effect observed. Whereas more work should be done to elucidate whether and how C1q interacts directly with T cells to modulate their function, the data thus far nevertheless demonstrate that C1q has a clear function in modulating T cell activation, at least indirectly, via APC-T cell interactions.
COMPLEMENT COMPONENT C3
Whereas the initiation of the complement cascade can occur via three distinct pathways-the classical, lectin, and alternative pathways-all three result in the formation of a C3 convertase (C4b2b or C3bBb) that proteolytically cleaves complement protein C3 into C3a and C3b [21] . C3a is a potent anaphylatoxin involved in the recruitment of leukocytes to the site of infection or injury, whereas C3b, as part of both C3 and C5 convertases, contributes to the continuation of the complement cascade and pathogen lysis and as an opsonin covalently linked to the activator that can induce ingestion by the phagocyte (reviewed in ref. [21] ). Additionally, Factor I cleaves C3b to iC3b and subsequently to C3d, the latter of which enhances B cell responses to antigen (ref. [22] and reviewed in ref. [23] ). Inherited complement C3
Ϫ/Ϫ was first described over 40 years ago [24] and results in recurrent pyogenic infections and immune-complex disorders, such as glomerulonephritis [25] . Subsequent studies reporting a C3 contribution to germinal center formation and antibody responses followed and have been validated with intermittent reports over a 40-year period; these reports have been recently reviewed elsewhere [23] . In this section, we will focus on the ability of C3 fragments to modulate T cell proliferation and differentiation, either directly (by interacting with receptors on the T cell) or indirectly (by interacting with receptors in an APC, which then influences T cell activation).
With the exploration of possible functions of C3 in T cell biology, Strainic and colleagues [26] showed in a murine system that after 1 h coculture with OVA peptide, C3aR and C5aR were up-regulated in mouse OT-II TCR transgenic cells and DCs in an antigen (OVA)-dependent fashion. Costimulatory signaling through CD28 on the T cell also induced C3aR and C5aR expression along with low levels of C3, Factor B, Factor D, and C5 [26] . Although these experiments did not show the specificity of the antibodies to C3aR and C5aR by using cells from C3aR Ϫ/Ϫ or C5aR Ϫ/Ϫ animals, functional studies using APC and T cells from C3aR Ϫ/Ϫ C5aR Ϫ/Ϫ animals and pharmacologic blockade of the two receptors did prevent the up-regulation of IFN-␥ (75%) upon antigen stimulation by APCs, providing support for a positive contribution of the signaling of these receptors in the induction of Th1 T cells.
The same group recently demonstrated that an absence of C3aR and C5aR signaling on murine CD4
ϩ T cells stimulated with anti-CD3 and anti-CD28 plus IL-2 resulted in enhanced production and secretion of IL-10, elevated TGF-␤ expression, and corresponding induction of Foxp3ϩ iT regs with robust suppressive activity. Chemical antagonism, as well as antibody blockade of C3aR and C5aR, also resulted in the elevation of functional human iT regs [27] (Fig. 2) . These data were supported by similar experimental results in human systems by Heeger and colleagues [28] and subsequently extended to nT reg in mice in vitro and in vivo [29] . That is, the absence of murine C3aR and C5aR signaling in thymus-derived CD4 ϩ Foxp3 ϩ nT regs resulted in elevated nT reg Foxp3 expression and promotion of nT reg function [29] . The C3a and C5a signaling pathways in all cells include activation of PI3K␥ and subsequently, Akt [26, 27, 29] , which although promoting Th1 activation in T regs , results in up-regulation of phosphorylated Foxp O1 (preventing Foxp3 induction [28, 29] ) and thus, preventing induction of suppressive activity-all positive activities for a host under invasion by a pathogen.
Other in vivo studies also support a role for C3 in diminishing regulatory cell function; that is, a lack of C3 correlates with T reg expansion and compromised T cell immunity in murine and human abdominal sepsis [30, 31] and that C3 Ϫ/Ϫ expands T regs to prevent induced autoimmune diabetes in a murine model [32] . None of these in vivo reports pinpointed whether C3a (or C3b or potentially subsequently generated C5a) was acting directly on the T cell or via an indirect, APC-mediated mechanism. However, the observations are consistent with the consequences of the absence of C3aR and C5aR described above.
Several studies investigating the expression of the C3aR failed to detect it on primary human T cells isolated directly from peripheral blood [33] or after anti-CD3 activation [34] (also reviewed in refs. [35, 36] ). However, activated T cells from patients with a severe inflammatory skin disease (atopic dermatitis) did express C3aR, whereas no expression of C3aR was found in T cells from patients with mild inflammatory skin diseases or from healthy subjects. When C3a was added to C3aR-expressing CD4 ϩ and CD8 ϩ T cells from the patients with severe inflammatory skin disease, a transient calcium flux within the T cells was observed, whereas this did not occur in C3aR-negative T cells [37] , validating the presence of a functional C3aR and suggesting a role for C3a on T cell function.
Thus, C3a certainly has a proinflammatory role on T cell function, perhaps as could be expected from activation of the powerful complement protective effector system during infection. Indeed, C3aR, but not C5aR, was found recently to be required for specific CD4 ϩ and CD8 ϩ T cell responses in lungdraining lymph nodes and critical for mouse survival during Chlamydia psittaci infections. It remains to be determined whether C3a was acting on the T cells directly or indirectly via APCs [38, 39] . Interestingly, another study investigating the role of C3 (but not specific C3 fragments) found that during primary Listeria monocytogenes infection, a lack of C3 dramatically reduces the proliferation of CD4 ϩ and CD8 ϩ T cells. Furthermore, anti-CD3-induced proliferation of CD8 ϩ T cells isolated from spleens of C3 Ϫ/Ϫ mice was significantly lower than CD8 ϩ T cells from C3-sufficient mice, suggesting that reduced CD8 T cell responses to L. monocytogenes in C3 Ϫ/Ϫ mice may be a result, at least in part, of the absence of direct C3 effects on CD8 ϩ T cells [40] . The effect of exogenously added C3a or C3 on the induced proliferation of the cells from C3 Ϫ/Ϫ mice would determine if this were a direct effect of these ligands or of downstream activation products. Going forward, experiments using mice with inducible and conditional deletion of C3aR (and C5aR) selectively in T lymphocytes will verify the function of these receptors in T cells (at least in mice) in disease models. [12] . In mice, C3 fragments bound to apoptotic cells may actively regulate the intracellular route of the cargo and delay DC phagosome maturation, thereby enhancing antigen presentation and T cell proliferation. (B) Based on refs. [26, 27] . In a murine system, the absence of C3aR on T cells or APCs leads to TGF-␤ production and iT regs , whereas the presence of the C3aR on T cells or APCs leads to an increase in T effs : Th17 and Th1, up-regulation of costimulatory ligands, such as CD28 and CD40 ligand (CD40L), and enhanced survival/expansion of T effs .
findings for enhancing the immune response to infection or suppressing autoimmune inflammation.
In addition to the effect of C3a on the induction of responses upon activation of T cells (whether by anti-CD3 and -CD28 stimulation or using the antigen-specific OT-I/II transgenic mouse system), some of the above-mentioned studies also provided evidence of a "tonic" role for locally (T cell) synthesized C5a and C3a. A new study has provided quite compelling data that indeed, intracellular C3a may have a critical survival function in human T cells and has provided clues to disparate results seen in mouse and human studies. In a series of intriguing confocal imaging and flow cytometry experiments conducted entirely in human cells, Liszewski and colleagues [34] demonstrated that C3 cleavage to C3a and C3b can occur intracellularly in activated protease CSTL. They showed that within 12 h of exposure to a (nontoxic) CSTL inhibitor (which prevented intra-and extracellular C3a generation), CD4
ϩ T cells underwent apoptosis associated with reduced mTOR phosphorylation. Cell viability could not be restored by addition of purified, exogenous C3a, supporting a role for intracellularly produced C3a in CD4 ϩ T cell survival. Additionally, reduction of intracellular T cell C3aR expression (by small interfering RNA) induced a decrease in mTOR activity and cell viability similar to that induced by the CSTL inhibitor, implying that intracellular C3a generation and C3aR ligation contribute to mTOR activity and overall T cell survival. The presence of a CSTL inhibitor, which eliminated only extracellular C3 cleavage, partially suppressed Th1 and Th17 cytokine responses, which could be partially rescued by adding exogenous C3a to the cell culture media and activating anti-CD46, suggesting that cell-surface generation of C3a and C3b contributes to the function of these T cell lineages [34] . Furthermore, T cells from patients with autoimmune arthritis demonstrated elevated intracellular C3a and phosphorylated mTOR with a trend for increased T cell IFN-␥ and TNF-␣ production [34] . Based on surface translocation of C3aR and CSTL induced on T cell activation (anti-CD3) and other supportive experiments using human cells, the authors concluded that in vivo TCR engagement would cause the intracellular C3aR and CSTL to be shuttled to the cell surface. Cell-surface CSTL would generate extracellular cell-surface C3a and C3b, which in turn, would engage C3aR and CD46, respectively, leading to induction of T eff functions [34] . Thus, in addition to the intracellular role of C3a on T cell survival, extracellularly generated, local C3 cleavage dictates certain T cell lineage responses. Importantly, this model is consistent with the observations that C3 Ϫ/Ϫ patients lack Th1 cell responses. In addition, this distinction between intracellular and extracellular C3 (especially C3a) explains why some C3 Ϫ/Ϫ patients (that produce intracellular C3a but not full-length C3) have T cells that proliferate but are deficient in proliferation and survival of IFN-␥ ϩ T cells [41, 42] . It is important to distinguish direct effects of C3 on T cells from the indirect, APC-mediated effect of C3a, shown to result in enhanced Th17 cells. C3a signaling on murine bone marrow-derived DCs has been shown to enhance production of IL-23 and IL-6 and suppress IL-10 production, promoting Th17 differentiation in experimental allergic asthma [43] . The high C3a plasma concentration in humans during acute asthma [44] is consistent with this effect. A study showing that C3 Ϫ/Ϫ mice demonstrated significantly lower GVHD mortality and morbidity after receiving WT bone marrow transplants, which was associated with lower numbers of Th17, Th1, and CD4 ϩ IFN-␥ ϩ IL-17 ϩ T cell subsets in secondary lymphoid organs, is consistent with a requirement for host production of C3 to facilitate these T eff populations and subsequent GVHD. Additionally, coculture of donor CD4 ϩ T cells with recipient C3
Ϫ/Ϫ APCs resulted in significantly reduced Th1 and Th17 responses relative to WT APCs, suggesting that C3 fragments from the APC modulate APC-mediated T cell subset induction [45] . However, these data could also be explained by a lack of local generation of C5a downstream of C3 activation [46] (or both), contributing to T eff function and GVHD pathology (see below, Complement Component C5). Nevertheless, considering all of the data in humans and mice, C3a has been shown to act directly on the T cell and indirectly via APC C3aR, triggering T cell activation to fight infection and promote inflammatory diseases.
Although less studied, there are several reports on how C3b affects T cell proliferation. C3b (along with C3a) has been shown to be necessary for proper human Th1 cell function via interactions with CD46 on the T cell (see below and reviewed in refs. [35, 36] ). However, in addition to direct T cell ligation, C3b bound to tetanus toxin results in enhanced antigen presentation to T cells in mice-or human-transformed cell lines [47, 48] . One study demonstrated that C3 is deposited on the surface of murine peritoneal macrophages in response to ␥-insulin injection, which then enhanced macrophage-dependent, antigen-specific T cell proliferation 2.5-fold when compared with macrophages of untreated animals. This effect was diminished by the presence of antibodies against C3 fragments, suggesting that C3 is enhancing macrophage-mediated, antigen-dependent T cell proliferation [49] . In a more recent study, Botto and colleagues [12] found that a complete lack of C3 significantly decreased overall T cell expansion induced by DCs that had ingested apoptotic cells in vivo but did not selectively affect the proliferation of particular T cell lineages relative to WT animals ( Fig. 2A) . Additional experiments in Factor I Ϫ/Ϫ animals suggested that the likely fragment involved was iC3b or C3dg (not C3b). However, CR3, the common receptor for iC3b, was not required, thus suggesting that an alternative receptor or mechanism is involved. The presence of the C3 fragments delayed colocalization of the apoptotic cells with lysosomes (i.e., delayed phagosome maturation) [12] , suggesting that this C3-associated delay facilitates MHC class II loading and enhanced antigen presentation [12, 50] . Interestingly, in humans, iC3b opsonization of apoptotic cells ingested by monocyte-derived macrophages results in macrophage polarization toward an anti-inflammatory phenotype, with NF-B inhibition and increased IL-10 secretion [51] . This suggests that in contrast to the effect of iC3b on apoptotic cells in mice enhancing antigen presentation by DCs [12] , human APC expression of iC3bRs could be responsible for an iC3b-triggered, anti-inflammatory phenotype in human macrophages.
Taken together, these data demonstrate that complement fragments C3a and C3b/iC3b have a direct role or indirect role, via APCs, in promoting T cell activation during infection, inflammatory disease, and homeostasis, although additional studies confirming and extending these data in human systems are still needed.
COMPLEMENT COMPONENT C5a
Hereditary complement component C5
Ϫ/Ϫ was first described in humans nearly 40 years ago. Serum from these individuals has a severely restricted ability to induce chemotaxis and an inability to generate the C5b-9 membrane attack complex. Consequently, these patients typically suffer from severe recurrent infections, especially Neisseria species [52] . C5a, along with C5b, is a product of C5 proteolytic cleavage by C5 convertase and is a very inflammatory molecule with potent chemotactic and anaphylatoxic properties [53] . However, whether C5a (via the C5aR) acts directly on T cells or via APCs acting on T cells has not been fully established, and there remain some conflicting reports on whether C5aR is expressed on the surface of T cells (particularly human T cells).
In mice, C5aR and C3aR mRNA were found to be up-regulated on T cells and DCs during T cell-APC cognate interactions in response to the OVA peptide in OT-II cells [26] . Moreover, IFN-␥ gene up-regulation induced by anti-CD3 and -CD28 stimulation of WT T cells was partially reduced in C5aR Ϫ/Ϫ T cells. In addition, the same group demonstrated that an absence of C3aR and C5aR signaling in CD4 ϩ T cells resulted in enhanced production of IL-10 and enhanced TGF-␤1 expression, which then mediated Foxp3ϩ iT regs with robust, suppressive activity [27] . As discussed above, a separate report demonstrated that signaling through C3aR and C5aR on mouse thymus-derived CD4 ϩ Foxp3 ϩ nT regs resulted in lowered nT reg Foxp3 expression and abrogated nT reg function [29] . Chemical antagonism, as well an antibody blockade of C3aR and C5aR, in combination with TGF-␤1, was shown to induce functional human iT regs from naive T cells incubated with autologous DCs, anti-CD3, and IL-2 (this was not observed with TGF-␤1 alone). That is, with the treatment of human CD45RA ϩ CD25CD4 ϩ T cells with C3aR and C5aR antagonists or monoclonal anti-C3 and -C5, Strainic and colleagues [27] demonstrated the acquisition of suppressive activity (and see figure in ref. [54] ). In contrast, however, in mice receiving a Plasmodium yoelii 17XL (malaria)-specific, whole-killed, bloodstage vaccine, C5aR (but not C3aR) signaling was found to be critical for the malaria-specific CD4 ϩ T cell response, not through direct effects on the expansion of the T regs (CD4 ϩ CD25 ϩ Foxp3 ϩ ) but rather, as a result of a deficiency in the ability of DCs to stimulate CD4 ϩ T cells [55] . In one recent, conflicting report looking at C5aR expression in murine T cells, Song and colleagues [56] engineered a GFP knockin mouse, in which GFP was inserted, such that GFP and C5aR were expressed under the C5aR promoter. They demonstrated that GFP is highly expressed in blood, spleen, and bone marrow Gr1ϩCD11bϩ cells and moderately expressed in circulating CD11bϩF4/80ϩ leukocytes and peritoneal macrophages as expected; however, no GFP was detected on resting T cells, T cells activated via TLR or antigen (OVA peptide in OT-I and OT-II transgenics), splenic myeloid, or plasmacytoid DCs [56] . Thus, future experiments using mice lacking C5aR in T lymphocytes only (conditional knockout) or adoptive transfer of WT T cells into C5aR Ϫ/Ϫ mice should clarify further the role of these receptors expressed in T cells.
In several studies, C5aR signaling in APCs has been shown to modulate T cell function indirectly. A recent report evaluated the role of C5aR (plus possibly C3aR) signaling in specific cell types during autoimmune arthritis. Elevated C3a and C5a levels (triggered by complement activation initiated by injected mannan or ␤-glucan particles into mice) were shown to promote production of proinflammatory cytokines by macrophages, resulting in spontaneous differentiation of CD4 ϩ T cells to Th17 cells, consequently initiating the development of autoimmune arthritis in SKG mice [57] . Naive, murine CD4 ϩ T cells, cocultured with autologous peritoneal macrophages in the presence of C5a and TGF-␤, differentiated into Th17 cells but not Th1 cells. In addition, in vivo macrophage depletion inhibited autoimmune arthritis in SKG mice, suggesting that C5aR signaling on macrophages is necessary (but not necessarily sufficient, as the authors did not rule out the contribution of C3aR) for the effect on Th17 differentiation and subsequent development of arthritis in this model [57] . Schmudde and colleagues [58] demonstrated that OVA antigen uptake and processing, as well as IL-1␤, IL-6, and IL-23 production, were impaired in C5aR Ϫ/Ϫ murine bone marrow-derived DCs, such that when these cells were adoptively transferred to WT mice, reduced Th17 cell differentiation associated with accelerated, activated T cell death resulted. Together, these studies provide substantial evidence for a role for C5a in modulating T cell function indirectly by altering the APC functional state.
In contrast, far fewer studies have evaluated a direct role of C5aR on human T cell function. Aside from the studies referenced above, in which C5aR and C3aR were antagonized in human T cells [27, 28] , an older study demonstrated that C5aR mRNA and protein expression were detected in human T cells after PHA stimulation [59] , but follow-up studies corroborating this result are lacking. Further work needs to be done to evaluate whether C5a interacts directly with T cells to modulate significantly induction and stability of iT regs in humans and to verify specifically human signaling pathways for future therapeutic manipulation.
ϳ30% of CD46
Ϫ/Ϫ individuals develop CVID [65] . Thus, CD46 appears to have regulatory as well as inflammatory functions.
Interestingly, a recent study identified a potential mechanism for this dual function of CD46 on T cells. Whereas original reports described CD46 as inducing a Tr1-like, IL-10-producing phenotype [66] , continued investigation using primary human cells led to the discovery that a CD46-mediated T cell lineage switch from IFN-␥-producing Th1 effector cells to IFN-␥ ϩ IL-10 ϩ and then IFN-␥ Ϫ IL-10 ϩ Th1 cells, in response to TCR-mediated activation, occurs at higher concentrations of IL-2. As a disease correlate of these in vitro studies, they also demonstrated that CD4 ϩ T cells from patients with rheumatoid arthritis are defective in the IFN-␥-IL-10 switch induced by CD46, presumably contributing to a hyperimmune state in vivo [67] . These findings were extended in a study of nT regs (that suppress autoactive immune responses) from 152 lupus patients [68] . Specifically, when purified nT regs from active and inactive lupus patients were stimulated with anti-CD3 under steady state, they were able to suppress Tconv in a cell contact-dependent fashion to the same extent as a healthy donor. This cell contact-dependent, suppressive function (i.e., nT regs activity) was, however, diminished by anti-CD3/CD28/ CD46 stimulation in the presence of IFN-␣, conditions, which mimicked the elevated C3b and IFN-␣ associated with in vivo SLE inflammatory conditions. Thus, whereas IFN-␣ plus ligation of CD46 increases IL-10 production by converting both nT reg and Tconv to Tr1 (IL-10-secreting) cells to suppress inflammation and prevent tissue damage, during SLE, when IFN␣ and TcR activation is excessive, nT reg activity is reduced, leaving the individual more susceptible to induction of further autoimmune responses [62, 68] .
A couple of recent studies evaluated whether this CD46-mediated costimulatory function could be retained in C3
Ϫ/Ϫ human T cells, if anti-CD46 were used in place of the natural ligand (which at the time, was unknown but postulated to be C3b). A unique study used purified CD4 ϩ T cells from a complement component C3 Ϫ/Ϫ individual treated with anti-CD3, anti-CD46, and IL-2, resulting in much lower IL-10 secretion relative to C3-sufficient control T cells; i.e., C3 Ϫ/Ϫ patients were also Tr1 Ϫ/Ϫ [41] . As the patient's T cells exhibited normal CD46 expression levels, the authors hypothesized that the lack of Tr1 induction (i.e., high IL-10 production) could have resulted from other impaired signaling in C3 Ϫ/Ϫ [41] . In a follow-up study, using two C3 Ϫ/Ϫ patients, they found that Th1, but not Th2, responses were impaired in both C3 Ϫ/Ϫ individuals [42] . However, when the authors reconstituted the C3 Ϫ/Ϫ T cell cultures with C3a and IL-2, Th1 and Tr1 induction (by anti-CD3 and -CD46) was restored in one of the C3 Ϫ/Ϫ patient's T cells but not the other. Thus, whereas the difference between the responses of these two patients remains to be identified definitively, these data, combined with the defective Th1 induction in CD46 Ϫ/Ϫ individuals, suggest that engagement of C3aR and CD46 is required for the CD46-mediated regulation of human Th1 cells and subsequent Tr1 induction [42] . This molecular pathway is thus substantially different from the requirements for murine Th1 induction, as mice do not express CD46 on most cells, and as described above, C3aR and C5aR (with C3a and C5a) contribute to the induction of IFN-␥-producing T cells in mice.
COMPLEMENT REGULATOR DAF/CD55
DAF (CD55) binds C3b and C4b to accelerate the decay of the alternative and classical pathway convertases, providing protection against amplified C3b deposition and complement activation on the plasma membranes of normal host cells. Genetic defects that result in reduction or loss of erythrocyte DAF lead to paroxysmal nocturnal hemoglobinuria [69] . Additionally, DAF germline mutation results in global DAF Ϫ/Ϫ associated with the "Inab phenotype" and Crohn's disease-like enteropathy in two cases [70] , but the causal relationship between DAF Ϫ/Ϫ and this enteropathy is not clear. DAF expression was first detected on human T cells nearly 30 years ago [71] and later, was found to be expressed on activated and naive T cells [72] . Over the past few decades, DAF, acting directly on the T cell or indirectly via APCs, has been shown to play an activating role or suppressive role, respectively, in T cell function. In humans, it was observed that T and B cell DAF and CD59 expression was diminished significantly in SLE patients with lymphopenia (associated with higher titers of autoantibodies) when compared with healthy donors. However, the opposite was found in T and B cells from nonlymphopenic SLE patients, suggesting that combined DAF and CD59 Ϫ/Ϫ may increase the susceptibility of cells to complement mediated lysis [73] but not necessarily pinpointing a role for T cell DAF-induced signaling in modulating T cell survival. However, in vitro studies with human T cells provide evidence that DAF does have a costimulatory function leading to T cell proliferation. For instance, one study used primary human T cells to demonstrate that when naive (CD45RA ϩ ) CD4 ϩ T cells were stimulated with anti-CD55/ DAF or plate-bound CD97 and anti-CD3 in the presence of IL-2, overall T cell proliferation was enhanced, T cell IL-10 production was enhanced substantially (tenfold), and IFN-␥ production was increased slightly (2.5-fold) [74] , demonstrating a direct effect of DAF on human T cell function. A subsequent report, in which peptide-loaded monocytes were cocultured with human T cell clones to approach more physiologic conditions of antigen presentation, found that blocking the interaction between DAF on human monocytes and CD97 on human T cells results in inhibition of T cell proliferation and IFN-␥ production (although IL-10 production was not measured in this study), presumably via blocking a contribution to stabilization of the immunological synapse. Whereas the mechanism for both of these findings remains to be defined, the data suggest that CD97 and DAF are another costimulatory pair involved in promoting T cell activation [75] . That is, the functional consequences of CD55 do not seem to be correlated with its decay-accelerating activity of cell-bound C3b and thus, the supply of complement activation fragments.
On the other hand, murine DAF seems to exert its effects via regulation of C3 convertase activity (i.e., C3a and/or downstream C5a). For example, DAF has been shown to play a role in preventing allograft rejection in vivo. One study demonstrated that in mice, donor DAF Ϫ/Ϫ allograft hearts were re-jected faster relative to WT allografts, and this rapid rejection in the absence of DAF was dependent on allograft production of C3 and subsequent C3-dependent, proliferative/prosurvival effects on a higher number of IFN-␥-producing, transplantspecific T cells. Interestingly, bone marrow-derived cells in the DAF Ϫ/Ϫ donor allograft hearts were found to drive the kinetics of graft rejection, consistent with the effect being related to C3 Ϫ/Ϫ cleavage regulation by the local DAF Ϫ/Ϫ APCs and thus, enhanced T cell function in the transplant [76] . This observation was supported by a similar lack of rejection with C3 Ϫ/Ϫ APCs. However, the decrease in T cell IFN-␥ production observed in the DAF-sufficient murine system containing heartbone marrow chimera cells (relative to DAF Ϫ/Ϫ ) could be a consequence of DAF modulating T cell function indirectly via APCs, as opposed to the direct DAF-CD97 costimulatory function observed in human T cells.
In another example, DAF Ϫ/Ϫ mice exhibited elevated T cell IFN-␥ and IL-2, as well as reduced IL-10 and enhanced T cell responses when these T cells were pooled and restimulated with antigen in vitro, consistent with a lack of control of C3 convertase activity, which would lead to increased local C3a and C3b generation and thus, Th1 activation. In vivo studies were consistent with this interpretation, as T cells from DAF Ϫ/Ϫ mice produced elevated levels of IFN-␥ and IL-2 relative to those of WT mice, and C3 Ϫ/Ϫ DAF Ϫ/Ϫ mice produced levels of IFN-␥ and IL-2 that were similar to those of T cells from WT mice [77] . This enhanced T cell cytokine production in the absence of DAF was dependent on APC expression of C3aR and C5aR and was correlated with decreased surface PD-L1 and increased CD40 expression, suggesting an indirect role of DAF in suppressing T cell activation as a result of limiting the generation of C3 cleavage products, such as C3a, and subsequent diminished C5 convertase activity (e.g., C3 and C5 fragments alter APC function to promote inflammatory T cell activity) [77] . Additionally, in a T cell-dependent EAE model [78] , DAF Ϫ/Ϫ accelerated disease. When the complement system was disabled by a genetic C3 Ϫ/Ϫ in the DAF Ϫ/Ϫ mice, however, the T cell lineage skewing and exacerbation of T cell-dependent EAE were diminished, demonstrating that again in this study, DAF is regulating T cell-dependent EAE via its regulation of the complement pathway. Similarly, during LCMV infection, DAF Ϫ/Ϫ mice had substantially greater LCMV antigen-specific T cell expansion, and these T cells exhibited greater killing capacity and cleared the virus more efficiently. However, when C3 or C5aR (CD88) was also absent, the DAF Ϫ/Ϫ mice no longer exhibited enhancement of CD8 ϩ T cell immunity, once again suggesting that DAF is regulating T cell immunity in a complement pathway-dependent fashion [79] .
In yet another murine model, DAF has also been shown to suppress IRBP-specific Th1 and Th17 responses and disease severity in murine EAU in a complement, pathway-dependent manner. EAU incidence and histopathology scores were significantly greater in DAF Ϫ/Ϫ mice with the EAU disease, and these mice exhibited up to sevenfold greater Th1 and fourfold greater Th17 responses against IRBP. Importantly, mice treated with soluble DAF protein exhibited decreased IRBPspecific Th1/Th17 responses and were protected from retinal injury relative to controls. This DAF-mediated regulation of enhanced Th1 and Th17 responses and subsequent EAU disease was found to be a result of DAF expression on APCs and T cells, which then modulated C3, Factor B, Factor D, and C5 production during their cognate interactions, consistent with an earlier report from Strainic and colleagues [26] , and implied that DAF is preventing IRBP-specific Th1/Th17 responses in a complement, pathway-dependent manner in this study.
Experiments, as described above, performed with DAF Ϫ/Ϫ mice have identified a role for the protein in indirectly regulating T cell activation via DAF on APCs and/or T cells via regulation of complement activity. However, it remains to be seen whether DAF can function similarly on human cells. Furthermore, studies using human APCs and T cells have uncovered a direct costimulatory role for DAF on T cells (via CD97 ligation), but a direct function for DAF on murine T cells has not been identified. Thus, future studies should aim to explore whether DAF plays a C3-dependent role on human T cell function and determine whether the observed human costimulatory mechanism of DAF on T cells is also occurring in mice as well as humans for the purposes of laying the groundwork for mechanistic studies in murine models' testing of therapeutic strategies.
CONCLUDING REMARKS
Long regarded as functioning strictly in the innate immune system, the complement system has, in the last few decades, been shown to have substantial contributions to directing or "sculpting" adaptive immunity, including T cell function. Complement protein C1q has been studied in human in vitro systems, underscoring a role for the protein in preventing inflammatory autoimmune T cell subset induction and proliferation, sometimes at apparent odds with observations, using genetically deficient murine models. Studies evaluating the interaction of C1q with primary human APCs, followed by coculture with T cells, approximate the sort of environment that may be present during low levels of inflammation in the tissue and highlight the immunoregulatory role C1q may be playing in this context (reviewed in ref. [6] ). These observations are consistent with the fact that C1q Ϫ/Ϫ humans develop lupus nearly 100% of the time, whereas how some of the in vivo mouse T cell [10] studies, to date, fit into the human and mouse C1q Ϫ/Ϫ phenotype scenario is not completely clear at this time [1, 2] .
Complement activation products C3a and C5a have been studied extensively in mice and have a clear role in directly and indirectly promoting T cell activation and proliferation and as such, promote/exacerbate allograft rejection, autoimmunity, and fighting infection. The C3a-C3aR axis plays similar roles in T cell survival and activation of T cells in humans and thus, suggests possible therapeutic interventions in enhancing or suppressing T eff activity. In the case of C5a, less corroborative data have been collected using human cells, making it difficult to translate definitively the murine results to human T cell immunity and disease. In vitro experiments with anti-C5 antibody Eculizumab may provide some insight [80] , but studies in C5 (continued on next page) patients would also be valuable in addressing this issue. However, studies with human T cells from healthy donors and patients afflicted with CVID or lupus have identified a clear role for CD46 (not expressed on most cells in mice) as an inflammation sensor on human T cells, which can depend strongly on the cytokine milieu. A novel surface interaction with the Notch 1 family Jagged 1, which appears to participate in the control of CD46-mediated modulation of T cell function, is another potential area for therapeutic modulation targets.
The effect of the complement regulator DAF has been studied on human and murine T cells, highlighting a direct role for the protein in costimulation of human T cell proliferation via CD97, while identifying an indirect role in regulating murine T cells (acting on APCs and/or by regulating generation of C3a and C5a). More studies are needed to understand whether DAF can influence human cells in an indirect fashion (e.g., in a C3-dependent role vs. CD97 ligation) as well. In vitro coculture experiments of APCs and T cells, with and without purified C3, C3 fragments, and other complement components and/or DAF inhibitors, may help elucidate whether such pathways exist.
In summary, although progress has been made toward understanding the role of complement proteins on T cell function during homeostasis and disease (Table 1) , more data are required to pinpoint the mechanisms involved and therefore, to identify targets for therapeutic intervention in human diseases. It is important to note that for several of the proteinsC1q, C3a, C5a, and DAF and CD46 (which is not even expressed in most mouse cells)-there are substantial differences between the data in human and mouse systems (in some cases, with opposite effects; see Fig. 2 in ref. [81] ). This underscores the importance of carrying out experiments in human cells or verifying that mechanistic pathways derived from murine in vivo systems are applicable to human systems to facilitate successful translational applications to the humans, such as therapeutic development [82] . Thus, a focus of future studies should aim to elucidate the role of complement components on T cell function in human systems, as the data gathered from such experiments will be more readily translated for therapeutic and/or preventative applications in human disease.
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